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BACKGROUND: Dogs with dystrophin-deficient muscular dystrophy are valuable models of 
the equivalent human disease, Duchenne Muscular Dystrophy (DMD): unlike the mdx mouse, 
2 
 
these animals present a disease severity and progression that closely matches that found in 
human patients. Canine models are however less thoroughly characterised than the 
established mdx mouse in many aspects, including gene expression. Analysis of expression in 
muscle plays a key role in the study of DMD, allowing monitoring and assessment of disease 
progression, evaluation of novel biomarkers and gauging of therapeutic intervention efficacy. 
Appropriate normalization of expression data via carefully selected reference genes is 
consequently essential for accurate quantitative assessment. Unlike the expression profile of 
healthy skeletal muscle, the dystrophic muscle environment is highly dynamic: transcriptional 
profiles of dystrophic muscle might alter with age, disease progression, disease severity, 
genetic background and between muscle groups. 
OBJECTIVES: The aim of this work was to identify reference genes suitable for normalizing 
gene expression in healthy and dystrophic dogs under various comparative scenarios. 
METHODS: Using the delta-E50 MD canine model of DMD, we assessed a panel of candidate 
reference genes for stability of expression across healthy and dystrophic animals, at different 
ages and in different muscle groups.  
RESULTS: We show that the genes HPRT1, SDHA and RPL13a appear universally suitable for 
normalizing gene expression in healthy and dystrophic canine muscle, while other putative 
reference genes are exceptionally poor, and in the case of B2M, actively disease-correlated.  
CONCLUSIONS: Our findings suggest consistent cross-sample normalization is possible even 
throughout the dynamic progression of dystrophic pathology, and furthermore highlight the 
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The fatal, X-linked, muscle-wasting disease Duchenne muscular dystrophy (DMD) affects 
roughly one in five thousand newborn boys [1], and is caused by insufficiency or absence of 
the muscle sarcolemma-associated structural protein dystrophin, a protein responsible for 
maintaining a physical link between the intracellular actin cytoskeleton and the extracellular 
muscle matrix environment. Loss of dystrophin weakens the sarcolemmal integrity of muscle 
fibres, leaving them sensitive to contraction-induced injury (especially eccentric contraction, 
where muscle fibres lengthen under tension) [2]. As muscle tissue is highly regenerative, the 
disease is typically characterised by continuous cycles of muscle degeneration and 
regeneration: regeneration that is sufficient to retain (albeit partially-compromised) muscle 
performance for the first few years of life. The ongoing process of muscle damage ultimately 
results in a persistent inflammatory state leading to progressive loss of muscle tissue and 
accumulation of fatty infiltrates and fibrotic scarring. DMD boys are thus often initially 
asymptomatic, displaying early signs of the disease between three and five years of age, losing 
ambulation between the ages of eight and fourteen and losing further muscle tissue 
thereafter. No cure for DMD presently exists, and while improved disease management (such 
as a programme of anti-inflammatory corticosteroid treatment) has led to significantly 
increased lifespans, DMD patients today typically die in their late twenties or early thirties 
from either cardiac or respiratory failure [3].  
Despite being an essentially monogenic condition, DMD varies considerably in severity and 
progression, a feature not shared by the dystrophin-deficient mdx mouse model. Dystrophin 
is an enormous gene with numerous splice variants: the varied site and nature of causative 
mutations influences the pathogenesis and also the choice of viable therapeutic approaches 
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[4-8]. The disease is further subject to influence from modifier genes, most of which remain 
poorly-characterised. Even on the comparatively consistent genetic backgrounds offered by 
mouse models, additional mutations in genes such as Annexin 6 substantially alter disease 
severity [9]. In human patients, mutations reducing expression of osteopontin [10, 11], or 
modulating signalling through TGFβ [12, 13] slow disease progression, and in dogs, muscle-
driven expression of the Notch ligand Jagged1 is associated with retained muscle function 
and increased longevity [14], as is downregulation of the phosphatidylinositol protein PITPNA 
[15]. It is likely that many thus-far undetected gene variants contribute to disease 
progression, and in more genetically outbred models (or indeed the enormous genetic 
diversity represented by the human population) such variability likely represents the norm.  
Within any given individual, the precise composition of muscle tissue varies considerably as 
the disease progresses, and indeed the cellular milieu present within a muscle may vary over 
even relatively small timescales in response to atypical muscle activity. Additionally, the 
extent of damage, rate of disease progression, and balance of fibrotic/adipogenic 
replacement differs considerably between muscle groups and with frequency of muscle use. 
In DMD patients, loss of ambulation invariably occurs before loss of upper limb mobility, and 
the diaphragm and intercostal muscles (muscle groups subject to essentially constant use and 
eccentric contraction) are among the most severely affected: these muscles show 
pronounced dystrophic pathology even in the otherwise relatively mildly-affected mdx 
mouse. In stark contrast, the extraocular muscles appear to be highly resistant to dystrophic 
pathology, retaining essentially unaltered function throughout the course of disease [16]. 
Taken together, this highlights the importance of ensuring that potential therapies are tested 
in more severely-affected, more genetically-diverse animal models such as the dog [17-19], 
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but also illustrates the challenges to performing direct individual-to-individual comparison of 
disease progression (and response to therapeutic intervention) in such models. 
 
Quantitative analysis of gene expression in dystrophic muscle: 
Measurement of gene expression in dystrophic muscle readily allows monitoring of disease 
progression and response to intervention, however such assessment is hampered by the 
innate variability described above. While semi-quantitative RT-PCR (and even nested RT-PCR) 
via gel densitometry is surprisingly commonplace in the DMD field, truly quantitative gene 
expression data is chiefly obtained via qPCR. The accuracy of this technique is critically-
dependent on good normalization: even with identical starting material, slight differences in 
the efficiency of RNA isolation or cDNA synthesis can significantly affect subsequent 
quantitation. Effective normalization requires appropriate reference genes, and indeed 
efforts to identify, validate and publicize such genes are becoming more common in a variety 
of disease states [20-24] and model organisms [25-30]. A review of the literature specifically 
within the DMD field however reveals a considerable number of candidates: selected 
examples in dystrophic dogs include GAPDH [31-33], RPS18 [34], HPRT1 [35, 36], 18S [37]; in 
humans, TBP and GUSB [13]; and in mice GAPDH [33, 38], ActB [39], 18S [40]. There appears 
to be minimal effort to apply reference genes consistently between studies (even varying 
from manuscript to manuscript within a research group), and data supporting the selection 
of the gene or genes used is rarely presented. Moreover, use of a single reference gene is 
common, despite MIQE guidelines [41]. Use of two or three such genes is, while demonstrably 
more expensive and time-consuming, nevertheless necessary for the generation of high-
quality data (especially in more genetically outbred models such as the dog) and is thus highly 
recommended [42]. Selection of such genes is by no means trivial even in reasonably 
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transcriptionally-static tissues, and becomes particularly challenging under conditions where 
a high degree of transcriptional plasticity might be expected (such as a progressive disease 
state). mRNA is typically subject to a higher rate of turnover than many proteins, and as a 
consequence even genes regarded as canonically ‘stable’ at the protein level (such as GAPDH 
or beta-actin) can vary significantly between samples, and indeed alter in expression over 
even relatively short timeframes [24, 43, 44]. This inherently dynamic behaviour of mRNA, 
combined with the progressive pathological changes associated with DMD, the differing 
severity dependent on muscle type and use, and the presence of modifier genes that worsen 
or ameliorate disease progression all potentially place severe restrictions on the studies that 
may be performed; such limitations make accurate comparisons of gene expression between 
individuals, between muscles, or over extended time periods, particularly difficult [45].  
Determination of a set of reference genes suitable for normalizing gene expression between 
individuals, between muscle groups and between age groups would therefore be beneficial; 
a unified set of genes suitable for all these categories combined would (if possible) be 
especially useful. The delta-E50 MD dog model of DMD [46] offers a perfect test case for 
identification of such reference genes. 
 
Determination of reference genes: 
Identification of suitable reference genes for qPCR normalization is by necessity somewhat 
convoluted: effective validation of a candidate reference gene would classically require 
comparison with an existing validated reference gene, essentially presenting an infinite 
regression problem. Several different methodologies have been proposed to circumvent 
these difficulties, each assessing suitability of candidate genes by subtly different criteria, and 
each thus exhibiting unique strengths and weaknesses. We typically employ three of these 
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methods, namely geNorm [47], Normfinder [48] and Bestkeeper [49]: all three require a 
dataset comprising gene expression data for a representative number of samples, for all the 
candidate reference genes, and all three use Microsoft Excel (as an executable macro, an add-
in and a write-protected spreadsheet, respectively) thus all three are readily accessible. 
Moreover, each program determines suitable reference genes via different algorithms: genes 
identified as high-scoring by all three methodologies are therefore likely to be strong 
candidates. 
A detailed consideration of the strengths and weaknesses of the three packages is provided 
(supplementary information 1), however the essential details and merits (and relevant links 
to software) are summarised below. 
 
geNorm analysis uses an iterative pairwise approach, identifying the pair of genes with the 
greatest pairwise correlation. The method does not assess overall expression stability, thus is 
tolerant of noisy datasets (but relatively sensitive to outliers). As a pairwise approach, the 
software identifies a minimum of two suitable genes (single candidates with greater stability 
will be ignored). A Microsoft-office compatible copy of the original excel macro is available at 
http://ulozto.net/xsFueHSA/genorm-v3-zip. 
 
Bestkeeper analysis compares individual expression profiles for each reference gene to a 
geometric mean profile generated from all gene candidates; in essence ranking the extent to 
which individual genes reflect the behaviour of the dataset as a whole.  





Normfinder analysis ranks individual gene candidates on overall expression stability, and can 
do so for the dataset as a whole, or within/between user-defined groups. Normfinder thus 
can identify suitable reference genes based on stability of expression alone: while this analysis 
thus handles noisy datasets poorly, it provides a valuable counterpart to the essentially 
pairwise methods of Bestkeeper and geNorm. 
The Normfinder plugin can be obtained from http://moma.dk/normfinder-software 
 
Study design: 
We present studies using a large sample set (81 muscle samples) obtained from the delta-E50 
MD dog model of DMD. Canine models offer several key advantages over mouse models: 
unlike the relatively mildly-affected mdx mouse model, dogs with dystrophin-deficient 
muscular dystrophy exhibit a pattern of disease progression far closer to that shown in human 
patients, with pronounced pathological muscle-wasting, progressive accumulation of fibrotic 
scarring and fatty infiltrates, and marked reduction in muscle performance [50]. Moreover, 
unlike the essentially maximally-inbred mouse model, delta-E50 MD dogs are maintained in 
a comparatively outbred state: female carriers are maintained in-house, but mated with 
externally-sourced stud males to generate healthy and dystrophic male progeny, reflecting 
the genetic diversity of the human population as a consequence. From a practical standpoint, 
the larger size of this animal model also readily permits repeated muscle biopsy from different 
sites within even a single muscle, thereby enabling within-animal studies and avoidance of 
accidental sampling of muscle tissue damaged by previous biopsy, a practicality that cannot 
be achieved in mice. 
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The delta-E50 MD model also offers a further advantage: the mutation falls within a common 
human hotspot, and is readily amenable to antisense oligonucleotide-based or other exon-
skipping therapeutics, requiring only ‘skipping’ of exon 51 for reading frame restoration.  
Our final sample set is comprehensive, comprising both diseased and healthy tissues, multiple 
genetically diverse individuals, several different ages and muscle groups, and moreover, 
incorporating both elements of consistency (multiple samples of matching muscle and age) 
and elements of marked diversity (inclusion of multiple muscle groups, including mandibular 
and extraocular muscles that in dogs uniquely express the 2M and EO myosin heavy chains, 
respectively). We have combined this collection of samples with a relatively large panel of 
reference genes (ActB, UBC, 18S, SDHA, RPL13a, YWHAZ2, B2M and HPRT1 –see table 1) to 
generate a dataset for use in the three software algorithms described above. Analysing this 
dataset in several configurations allowed us to determine appropriate reference genes for 
normalizing expression under various specific constraints, revealing reference genes that 




Animal cohorts and tissue collection: 
Maintenance of the dystrophic delta-E50 MD dog colony and biopsy for the natural history 
study were conducted under Project Licence approval from the UK Home Office and following 
approval from the Royal Veterinary College Ethics and Welfare committee. 
Nine male dogs (5 dystrophic, 4 healthy) from the colony were used for study of age-related 
gene expression, with biopsy samples collected from the left vastus lateralis muscle under 
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general anaesthesia at three month intervals, up to a maximum age of eighteen months as 
part of a larger natural history disease characterisation. Where possible, dystrophic and 
healthy littermates were used for each time-point, with samples being collected as dogs of 
the appropriate age became available. Final coverage thus consists of: 3 months, N=8 (5:3 
DMD:WT); 6 months, N=7 (3:4); 9 months, N=5 (2:3); 12 months, N=4 (2:2); 15 months, N=4 
(1:3); 18 months, N=5 (2:3). One healthy dog from this cohort (G2) was subsequently 
euthanized at 18 months of age to provide a panel of muscle types, and D1 and D2, two 
additional dogs (dystrophic littermates) were added to provide a similar panel of dystrophic 
muscles (samples collected post-mortem following humane end-point euthanasia). As the 
ages of these latter dogs at euthanasia (14 and 17 months, respectively) were close to the 15 
and 18 month age brackets defined above, these samples were also included in several 
comparisons of age-related gene expression (see supplementary figure 1 for IDs, litter 
matching, genotypes, muscle groups and ages). Immediately following collection, muscle 
samples (approximately 1cm3) were mounted on cork blocks on a bed of OCT (Tissue-Tek) and 
snap frozen under liquid-nitrogen-cooled isopentane to preserve tissue morphology. 
Frozen tissues were used for histological serial cryosectioning (as part of a separate study), 
with interleaving (unmounted) sections collected for isolation of the RNA used in this study 
(50-100 8um sections per sample, ca. 40-100mg tissue). 
 
RNA isolation and cDNA synthesis: 
Frozen tissue sections were rapidly mixed with RNA-Bee reagent (Amsbio) and RNA extracted 
following the manufacturer’s instructions (with inclusion of an additional 1:1 chloroform 
extraction following phase separation, and inclusion of glycogen at 10ug.ml-1 during 
precipitation to maximise RNA yield). RNA purity was confirmed by nanodrop (ND1000), with 
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samples exhibiting significant guanidium carryover (260/230<1.7) further cleaned by a second 
isopropanol precipitation step. 
cDNA was prepared from RNA using the RTnanoscript2 kit (PrimerDesign) using random 9mer 
and oligodT priming, with 1.6ug of total RNA per 20ul reaction. Following synthesis, cDNA 
samples were diluted (1/20) to minimise PCR-inhibitory contributions from cDNA synthesis 
buffer components, giving a final cDNA concentration of approximately 4ng/ul (assuming 1:1 
conversion of RNA to cDNA). 
 
qPCR and analysis: 
qPCR reactions were performed in duplicate or triplicate with 2ul cDNA per well (approx 8ng), 
using PrecisionPLUS SYBR green mastermix (PrimerDesign) with primers to ActB, UBC, 18S, 
SDHA, RPL13a, YWHAZ2, B2M and HPRT1 (see table 1) taken from the geNorm Canis familiaris 
set (PrimerDesign), and primers to Myf5 and MEF2C designed using primer3 software 
(http://primer3.ut.ee/). PCR was conducted in a CFX384 light cycler (BioRad) with Cq values 
determined via regression.  
MEF2C Fwd: 5’-GCAAGCAAAATCTCCTCCCC-3’ 
MEF2C Rev: 5’-TGGGGTAGCCAATGACTGAG-3’ 
Myf5 Fwd: 5’-CGGCCTGCCTGAATGTAAC-3’ 
Myf5 Rev: 5’-AATCCAGGTTGCTCGGAGTT-3’ 
All primer pairs gave sharp, single amplicon products and single melt peaks: for additional 
details (cycling conditions, quality checks, melt curves) see supplementary info 2. 
Candidate reference genes were analysed using geNorm, NormFinder and Bestkeeper, using 
the Windows 7 operating system and Excel 2003 or 2010 (Microsoft). Bestkeeper analysis 
used raw Cq values, while for geNorm and NormFinder, values for each gene were linearized 
13 
 
by conversion to relative quantities (RQ). Analysis was performed on the dataset as a whole, 
or using subsets of data as described below. 
geNorm and Bestkeeper: 
RQ data (or raw Cq data, respectively) were entered into the geNorm/Bestkeeper excel 
macros in the following combinations: 
 Entire dataset (all dogs, all muscles, all ages)  
 Natural history samples (vastus lateralis muscles, all ages) 
 Natural history dystrophic samples (dystrophic vastus lateralis, all ages) 
 Natural history healthy samples (non-dystrophic vastus lateralis, all ages) 
 Dystrophic samples (all muscles, all ages, dystrophic only) 
 Healthy samples (all muscles, all ages, healthy only) 
 Muscle panel (all muscles, two ages) 
 Healthy muscle panel (all muscles, single age, healthy only) 
 Dystrophic muscle panel (all muscles, two ages, dystrophic only) 
Normfinder: 
As described above, the Normfinder algorithm can be used with datasets as a whole, but also 
offers the option of grouping data in a user-dependent fashion: allowing measurement of 
between-group and within-group variation for a potentially large number of grouping criteria.  
Our Normfinder analysis therefore used two approaches: ungrouped, assessing expression 
variation overall, using the entire (RQ) dataset or selected subsets exactly as described for 
geNorm and Bestkeeper (above), or grouped, looking at variation in expression over the entire 
dataset (or subsets as above), between specific, user-specified groups. Note: several samples 
were necessarily omitted under specific grouping criteria where groups of one sample would 
result (for example ‘by individual’) as groups must contain at least two samples. This latter 
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analysis can be particularly useful not only for identifying universally-suitable reference genes 
but also for isolating group-specific genes (such as a gene showing strong variation with age, 
or muscle type). Dataset elements and groupings were as follows: 
 Entire dataset 
o By age 
o By individual 
o By healthy/diseased 
o By litter 
 Dystrophic animals only 
o By age 
o By individual 
o By litter 
 Healthy animals only 
o By age 
o By individual 
o By litter 
 Natural history dogs only 
o By age 
o By individual 
o By healthy/diseased 
o By litter 
 Muscle panel 
o By age 
o By individual 
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o By healthy/diseased 
All other analyses (Spearman correlations, Mann-Whitney U tests) were carried out using 
GraphPad Prism 7.02. 




Individual Cq values fell within a relatively consistent range for any given gene, with the 
greatest sample-to-sample variation observed in ActB and the least in 18S (see supplementary 
figure 2). With the exception of the abundantly-expressed 18S ribosomal RNA, the candidate 
genes examined covered a total Cq range of over 13 cycles, equivalent to differences in mRNA 
expression of around 4 orders of magnitude.  
 
GeNorm analysis:  
The iterative pairwise approach of the geNorm algorithm ranks genes by average expression 
stability (M), where lower scores represent higher stability. As shown (table 2, figure 1 and 
supplementary figure 3), RPL13a, HPRT1, 18S and SDHA were universally scored as the highest 
ranking genes (lowest expression stability value), and indeed RPL13a and HPRT1 were ranked 
as the highest scoring pair by the geNorm algorithm for all but one of the dataset 
combinations (the only exception provided by the dataset of healthy quadriceps samples 
alone, where RPL13a was paired with 18S instead, with HRPT1 falling to the next highest 
rank). The commonly accepted geNorm threshold for suitable reference gene stability is 
M<0.5 (bold gene names in table 2, dashed line in figure 1 and supplementary figure 3), thus 
16 
 
while 18S and SDHA fall just outside this threshold under several dataset combinations, 
RPL13a and HPRT1 are consistently ranked as suitable reference genes by the geNorm 
algorithm. Interestingly, by this metric, fully 6 of the 8 genes were ranked as suitable for our 
healthy muscle panel (figure 1b), though ActB (beta-actin) scored comparatively poorly under 
all dataset combinations, even those assessing healthy muscle alone. 
The geNorm algorithm also calculates the pairwise variation arising from inclusion of 
additional reference genes, in essence indicating whether the ‘best pair’ is sufficient, or 
whether better normalization can be obtained by use of 3 or more genes. In all cases, 
increasing number of reference genes to 3 or 4, lowered overall variation (supplementary 
figure 4), however values below 0.2 are considered acceptable [47], and the suggested pair 
of genes was sufficient to pass this threshold in every instance. 
 
Bestkeeper analysis: 
The Bestkeeper spreadsheet generates a large quantity of data, however the most useful 
output metric tends to be the coefficient of correlation (r): the extent of correlation between 
a given reference gene and the ‘bestkeeper’ (a composite derived from all candidate 
reference genes), where higher values represent greater correlation. In essence, this value 
reveals the individual gene that best reflects the behaviour of the dataset as a whole. As 
shown (table 3, figure 2, supplementary figure 5), HPRT1 and SDHA tended to rank highly 
under most combinations, with RPL13a also scoring highly (though usually of lower rank). In 
marked contrast to geNorm analysis, YWHAZ2 and B2M also tended to perform well. There is 
no established threshold Bestkeeper correlation value for ‘good’ reference genes (thresholds 
shown in table 3 are for comparative purposes only), however the data shows a tendency 
toward a sharp divide between low and high correlation (figure 2, supplementary figure 5): 
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poor candidates are very poor, while often 5 or more of the remaining genes score 
comparatively highly. 
As with geNorm, ActB was near-universally scored as the least suitable reference gene. Only 
UBC and 18S displayed comparably poor suitability. Also in agreement with geNorm analysis, 
when our healthy muscle panel was analysed alone (figure 2b), the majority of our candidate 
genes (all except ActB and 18S) showed high correlation with the ‘bestkeeper’ (r > 0.85). 
Normfinder analysis: 
Ungrouped analysis (table 4, figure 3 and supplementary figure 6), assessing overall 
expression stability in the entire dataset, or in subsets as for geNorm and Bestkeeper (above) 
revealed that SDHA and HRPT consistently scored highly (low stability value) under essentially 
all combinations examined, with YWHAZ2 also performing well (especially under dystrophic 
conditions alone). As with the geNorm and Bestkeeper analyses, ActB was again near-
universally ranked as the least appropriate candidate, however (similar to Bestkeeper, but in 
marked contrast to its ranking under geNorm), RPL13a here often ranked comparatively 
poorly (with the exception of the healthy muscle panel). As with Bestkeeper analysis, there is 
no conventional threshold value for Normfinder suitability, however regardless of absolute 
value, a stark difference was observed between ActB and essentially every other candidate 
gene: the ‘poor score’ for RPL13a was thus typically only marginally worse than the ‘high 
score’ for SDHA. An examination of absolute stability values also reiterates the transcriptional 
homogeneity of our healthy muscle panel suggested by geNorm and BestKeeper analysis: fully 
5 of our 8 candidate genes exhibited values below 0.2, something no single gene was able to 
achieve in the matching dystrophic muscle panel (figure 3b).   
Under grouped analysis (table 5, supplementary figure 7, supplementary table 1), a more 
mathematically-sophisticated comparison assessing both intergroup and intragroup 
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variation, a similar pattern was observed. Again SDHA and HPRT1 scored highly essentially 
regardless of grouping criteria, while RPL13a was less favoured. Normfinder grouped analysis 
additionally provides a ‘best pair’: a pair of genes that in combination outperform the highest 
scoring single candidate (note: these genes need not themselves be the highest scoring 
individually –a pair of genes that vary considerably, but in opposite directions, can combine 
to provide more accurate normalization). In almost every instance, SDHA or HPRT1 comprised 
one member of the ‘best pair’, further supporting the suitability of these reference genes. We 
note however that these genes were rarely suggested together: instead YWHAZ2 was near 
universally suggested as a partner. This gene also notably scored reasonably highly under all 
combinations and groupings save those of healthy dog samples alone. 
 
Further validation: 
HPRT1 and SDHA ranked highly under essentially all algorithms and conditions, both in 
pairwise variation and stability, while RPL13a showed marked pairwise correlation with 
HPRT1 and a tendency to score (if not necessarily rank) highly under most conditions, 
especially those assessing healthy muscle alone. Conversely, Bestkeeper analyses showed a 
marked tendency to score B2M (beta-2-microglobulin) highly while both geNorm and 
Normfinder algorithms suggested the reverse, especially when comparing both healthy and 
dystrophic samples (tables 2, 3 and 4): notably, while showing a high correlation with the 
‘bestkeeper’, B2M showed much lower correlation with other individual gene candidates. As 
geNorm assesses by pairwise comparison, and Normfinder by overall stability, the implication 
is that B2M exhibits low expression stability but also potent influence over the dataset as a 
whole: a hallmark of a strongly disease-associated gene. To confirm this hypothesis and 
validate our selected reference genes, B2M expression data for our natural history samples 
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were normalized using the geometric mean of SDHA, RPL13a and HPRT1 (in essence, using 
high-scoring reference genes to normalize potentially disease-associated genes). As shown in 
figure 4a, B2M expression is significantly enhanced in dystrophic muscle, by approximately 
two-fold when compared with healthy muscle. 
To further confirm the suitability of our nominated reference genes, we additionally 
measured (and normalized) expression of the myogenic transcription factors Myf5 and 
MEF2C –markers of actively regenerating muscle. As shown in figure 4b and c, both these 




Canine models of muscular dystrophy are increasingly coming to represent a key translational 
element in the study of this disease, exhibiting disease severity and progression (and 
concomitant loss of muscle performance) in a manner that closely-mimics the human 
condition [17-19]. As measurement of gene expression is a major component of the 
investigative toolset, a panel of reference genes suitable for normalizing measured expression 
data in this animal model under a multitude of different conditions would be highly beneficial, 
and would moreover support the hypothesis that a similarly broadly-applicable set of genes 
might be found for human samples. The data presented here strongly suggest that HPRT1 and 
SDHA (and to a lesser extent, RPL13a) are suitable candidate reference genes for normalizing 
gene expression in both healthy and dystrophic canine muscle, being consistently ranked 
highly when comparing muscle samples taken at different ages (and thus in dystrophic 
muscle, stages of disease progression), between different individuals, and even between 
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different muscles (including selectively-spared muscle groups such as the extraocular 
muscles). It should be noted that ‘highest ranking’ need not necessarily imply ‘high scoring’: 
any panel of genes, even one comprised entirely of those known to be highly dysregulated in 
DMD, would be nevertheless ranked in order of expression stability by these software 
programs (effectively producing a ranking of ‘terrible stability’ to ‘poor stability’). Our data 
here shows however that not only are SDHA, HPRT1 and RPL13a near-consistently high-
ranking, they are also consistently high-scoring: being both the favoured genes from our 
candidate panel, and also empirically highly stable. 
This finding in itself is somewhat surprising: the transcriptional environments represented by 
these different samples are likely to be highly diverse, and it was by no means guaranteed 
that any candidate genes would be suitable under all circumstances. Indeed, even if such a 
set of genes existed, it was a distinct possibility that these genes would, rather than being 
strong reference genes, instead simply be the ‘least poor’ at normalizing expression within 
these diverse environments (with distinct condition-specific combinations of reference genes 
being genuine strong candidates). As our data show however, this is not the case: the 
nominated reference genes are of comparable stability when analysed as specific categories 
(age, individual, disease) as they are when employed as an entire dataset. 
Interestingly, analysis of a panel of healthy muscles alone (multiple muscles from one healthy 
individual) yields markedly greater stability values for all candidate genes than any dystrophic 
or combined dataset, and greater values than a single healthy muscle type (vastus lateralis) 
over time. This finding highlights the stark differences in transcriptional activity between 
healthy and dystrophic muscle and further suggests that age plays a greater factor in 
transcriptional profile than muscle type: adult (healthy) muscle tissue appears 
transcriptionally highly conservative regardless of which muscle is examined. Even within 
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such a stable environment, however, SDHA, HRPT1 and RPL13a remained very high-scoring 
candidates. 
 
RPL13a codes for a protein component of the 60S ribosomal subunit, and thus might 
reasonably be expected to show high stability under resting conditions: protein synthesis 
being one of the few constant requirements of virtually all cells. Given the stark changes in 
cellular composition between healthy and dystrophic muscle, however, it is perhaps 
surprising that the translational demands of the tissue as a whole appear to remain 
consistent. One might also expect RPL13a to closely-mirror the expression of 18S ribosomal 
RNA (a common choice of reference gene [37, 40]): while the two are indeed scored closely 
under several conditions, this is not universal. Moreover, only the protein and the rRNA need 
strictly correlate: as an mRNA, RPL13a is subject to further amplification at the translation 
stage, while 18S ribosomal RNA is not. As our study shows (see Cq values, supplementary 
figure 2), while expression of RPL13a is the highest measured for all candidate mRNAs, it is 
still lower in absolute expression than 18S by almost 2 orders of magnitude.  
HPRT1 codes for hypoxanthine phosphoribosyltransferase 1, an enzyme involved in purine 
biosynthesis via the salvage pathway [51]. While such an important function readily suggests 
a housekeeping role, the implication that metabolic requirements for purines are similar 
between healthy and dystrophic muscle is an unexpected finding (the former being largely a 
post-mitotic tissue, the latter a highly dynamic regenerative environment). The authors note 
that this gene has been proposed as a suitable reference gene by others [35, 36].  
SDHA (succinate dehydrogenase subunit A) represents a more classical finding, being a 
ubiquitous mitochondrial enzyme component and thus also a gene strongly associated with 
mitochondria-rich skeletal muscle. Expression of this gene appears very stable, particularly 
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over time: all our quadriceps biopsy samples exhibit near-uniform expression regardless of 
disease, individual or age. This was unexpected: dystrophic muscle is subject to pathological 
wasting as disease progresses, thus the percentage of a given dystrophic sample that is 
functional muscle necessarily falls with age. It is however widely recognised that the more 
highly-oxidative fibres (i.e. type I) are selectively spared as disease progresses, with losses 
primarily incurred by the faster glycolytic fibres (2A and in particular, 2X) [52]. Our data here 
thus suggests not only that SDHA is a suitable reference gene, but also by implication that 
regardless of fibre loss, the oxidative capacity of dystrophic muscle (as measured by SDHA 
expression) does not significantly decrease over time in this model. 
 
The samples used to prepare our dataset were selected to offer relatively comprehensive 
coverage of potential variability, and thus included healthy and diseased tissue, tissues of 
different ages, taken from different individuals, and including multiple muscle groups. A 
number of caveats must nevertheless be acknowledged: the multiple muscle groups included, 
while extensive, were derived from only 3 individual animals (D1, D2 and G2), two of whom 
were dystrophic littermates. These samples comprise more than half our entire sample set, 
thus our ‘total’ dataset is inherently weighted toward these 3 individuals, and toward 
dystrophic muscle as a whole (though this latter is perhaps less contentious given the focus 
of this work). Similarly, our panel of age-matched healthy/dystrophic biopsy samples, 
assessing disease progression over time, are exclusively derived from a single muscle (the 
vastus lateralis) thus our analyses ostensibly identify reference genes suitable for normalizing 
expression over time in this muscle alone. Lastly, due to the relatively nascent nature of our 
delta-E50 MD dog colony, only 5 animals (3 healthy, 2 dystrophic) were of sufficient age to 
contribute to the full course of age-selected muscle samples: younger samples are thus over-
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represented (see supplementary figure 1). These limitations accepted, we nevertheless feel 
that our panel of samples provides a good coverage of the most likely sources of variation 
when analysing dystrophic/healthy muscle, and that our conclusions regarding the broad 
utility of our reference gene candidates are thus justified. 
 
A puzzling finding was the tendency of Normfinder analysis to rank RPL13a among the lowest 
scoring genes, while concomitantly nevertheless agreeing with Bestkeeper and geNorm as to 
the suitability of SDHA and HPRT1. Indeed, via the pairwise ranking of geNorm, RPL13a and 
HPRT1 were almost universally placed as the most closely-correlated pair. As shown in figure 
5, the 2 genes exhibit highly-correlated expression values for the dataset (Spearman’s rho 
correlation of 0.87, compared to 0.57 and 0.47 for HPRT1/SDHA and RPL13a/SDHA 
respectively), thus one might expect these 2 to be ranked similarly by all 3 software 
algorithms. As noted above however, our Normfinder analysis tended simply to single out 
ActB: this gene was near-consistently placed last, and by a considerable margin, with the 
other candidate genes tending to be relatively close-matched in stability (see figure 3 and 
supplementary figures 5 and 6). The Normfinder algorithm scores genes by individual stability 
of expression (rather than by pairwise comparison to other genes, or to a gestalt of all genes 
examined) thus unlike geNorm or Bestkeeper, stability and correlation are not intrinsically 
linked. Minor variations in overall expression stability could well account for the lower score 
of RPL13a despite its clear pairwise correlation with HPRT1, and we do not thus consider the 
poor Normfinder performance of this gene to be sufficient grounds for discarding it from our 
lead candidates. All 3 algorithms thus appear (with caveats) to reach near-uniform consensus 
regarding strong reference gene candidates, and furthermore all 3 methods also scored ActB 
(beta-actin) as the least suitable candidate under essentially all conditions. This gene 
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exhibited the widest range of Cq values (supplementary figure 2), and we have previously 
shown ActB to be an exceptionally poor reference gene in cultured differentiating myoblasts 
derived from healthy and dystrophic mice [27]. Our data here thus supports the hypothesis 
that ActB is a poor choice of reference gene for muscle-derived samples as a whole (though 
we also note this gene has been employed as a reference in mdx mice [39]). 
 
Beyond simple identification of suitable reference genes (and concomitantly, poor reference 
genes), an advantage of using such a broad sample set is the potential to identify condition-
specific gene regulation. While the pairwise correlation algorithm of geNorm is less useful in 
this respect (as genes are never considered in isolation), the individual gene stability 
assessment of Normfinder (and the facility for user-determined grouping) is potentially very 
powerful. Our analysis allowed us to single out B2M (beta-2-microglobulin) as a candidate 
gene likely to exhibit disease-specific changes in expression, and further (by normalizing with 
our high scoring reference genes) allowed us to confirm that this gene is upregulated by 
approximately 2-fold in dystrophic muscle, thus illustrating the power of our approach. While 
such a DMD-specific upregulation has not to our knowledge been previously reported (though 
B2M has been noted to be a poor scoring reference gene in the muscle of mdx mice, along 
with ActB [38]), this finding is perhaps not entirely surprising: B2M is (in humans and mice) 
canonically relatively poorly-expressed in muscle, but highly expressed in immune lineages 
[53, 54], thus the persistent inflammatory state characteristic of dystrophic muscle may well 
lead to a marked enhancement of B2M gene expression.  
To further confirm the validity of our selected reference genes, we measured expression of 
the basic helix-loop-helix (bHLH) myogenic factor Myf5 and the myocyte enhancer factor 
MEF2C in our natural history muscle samples. While both of these genes are expressed in 
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healthy muscle (MEF2C is constitutively expressed by myonuclei, and Myf5 is found in the 
satellite cell population and in muscle spindles [55, 56]), these transcription factors are 
strongly induced during myogenesis and would thus be expected to be significantly 
upregulated in muscle undergoing active regeneration. As expected, both these genes (after 
normalization) exhibit highly significant dystrophy-associated increases in expression, to an 
extent comparable with B2M. 
 
We thus present the encouraging finding that, for the purposes of normalizing gene 
expression in dystrophic and healthy dog muscle - regardless of muscle type, individual or 
age- the genes SDHA, HPRT1 and RPL13a appear universally suitable, and that several other 
candidate genes are not only unsuitable, but even actively disease-associated. Our work thus 
also illustrates the importance of empirically determining suitable reference genes for 
quantitative analysis, and addresses the limitations and advantages of the various software 
algorithms a researcher might employ toward this end. 
While this discovery should prove of considerable benefit to further studies of this animal 
model in particular, we cannot at present confirm whether these findings extend to other 
canine models such as the GRMD dog. The fact that these genes are high scoring under such 
varied conditions would tend to support this assertion, however: we deem it unlikely that 
expression differences between two breeds of Canis familiaris would surpass that between 
young healthy muscle and aged dystrophic muscle.    
A wider revelation of this work is that such broadly-applicable reference gene candidates exist 
at all (and can be empirically determined). While we stress that our data should not be taken 
to imply that HPRT1, RPL13a and SDHA are appropriate for human samples, our data 
nevertheless support the hypothesis that a similar trio of genes might be found for 
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normalizing gene expression in biopsy samples taken from human patients. Such studies are 
beyond the scope of our current investigations (requiring access to a similarly broad collection 
of patient muscle samples and a concomitant suitable panel of human-specific candidate 
genes), but our work here suggests such an effort might well yield success. A standard panel 
of reference genes suitable for quantitative analyses in human samples (regardless of disease 
state, age or individual genetic background) would potentially permit independent studies 
and trials to be quantitatively compared, and would thus be of considerable benefit to the 
field. 
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Gene Name Full name 
HPRT1 Hypoxanthine phosphoribosyltransferase 1 
18S 18S ribosomal RNA 
RPL13a Ribosomal protein L13 
SDHA Succinate dehydrogenase subunit A 
YWHAZ2 Tyrosine 3-Monooxygenase/Tryptophan 5-
Monooxygenase Activation Protein, Zeta 
B2M Beta 2 Microglobulin 
UBC Ubiquitin C 
ActB Beta Actin 
 


















































 SDHA SDHA SDHA 18S 18S HPRT SDHA SDHA UBC 
 18S 18S 18S SDHA UBC SDHA 18S 18S SDHA 
 UBC YWHAZ2 B2M UBC SDHA UBC YWHAZ2 YWHAZ2 YWHAZ2 
 YWHAZ2 B2M UBC B2M B2M B2M UBC B2M 18S 
 B2M UBC YWHAZ2 YWHAZ2 YWHAZ2 YWHAZ2 B2M UBC ActB 
Least 
stable 
ActB ActB ActB ActB ActB ActB ActB ActB UBC 
 
Table 2: geNorm rankings 
geNorm results for the entire dataset or subsets (as indicated), ranked from highest scoring 
pair (top) to least stable candidate (bottom). Bold: score < 0.5 (threshold for suitability); 







Table 3: Bestkeeper rankings 
Bestkeeper results for the entire dataset or subsets (as indicated), ranked (top to bottom) by 




























B2M B2M B2M SDHA SDHA B2M B2M HPRT RPL13a 
 SDHA HPRT SDHA HPRT B2M SDHA YWHAZ2 B2M HPRT 
 YWHAZ2 SDHA YWHAZ2 B2M HPRT HPRT HPRT RPL13a SDHA 
 HPRT YWHAZ2 UBC YWHAZ2 UBC YWHAZ2 RPL13a YWHAZ2 B2M 
 RPL13a RPL13a HPRT UBC YWHAZ2 UBC SDHA SDHA YWHAZ2 
 UBC 18S ActB RPL13a 18S RPL13a 18S 18S UBC 
 18S ActB RPL13a 18S RPL13a ActB ActB ActB 18S 
Least 
stable 




























SDHA SDHA SDHA SDHA SDHA SDHA SDHA YWHAZ2 RPL13a 
 HPRT YWHAZ2 HPRT HPRT YWHAZ2 HPRT HPRT 18S SDHA 
 YWHAZ2 HPRT B2M YWHAZ2 HPRT B2M YWHAZ2 SDHA UBC 
 RPL13a 18S UBC UBC B2M RPL13a RPL13a HPRT YWHAZ2 
 18S B2M RPL13a 18S UBC UBC 18S B2M HPRT 
 UBC RPL13a YWHAZ2 RPL13a 18S YWHAZ2 B2M RPL13a 18S 
 B2M UBC 18S B2M RPL13a 18S UBC UBC ActB 
Least 
stable 
ActB ActB ActB ActB ActB ActB ActB ActB B2M 
 
Table 4: Normfinder rankings (ungrouped) 
Normfinder results for the entire ungrouped dataset or subsets (as indicated), ranked (top to 
bottom) from highest scoring (lowest stability value) to lowest scoring. Bold: stability <0.5; 
italics: stability > 1.0 
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SDHA SDHA HPRT SDHA SDHA SDHA SDHA SDHA B2M B2M 
 HPRT HPRT 18S HPRT YWHAZ2 YWHAZ2 YWHAZ2 B2M SDHA SDHA 
 B2M YWHAZ2 RPL13a UBC B2M HPRT HPRT HPRT HPRT HPRT 
 YWHAZ2 18S SDHA YWHAZ2 HPRT B2M B2M UBC 18S 18S 
 18S B2M UBC 18S UBC 18S UBC YWHAZ2 UBC RPL13a 
 RPL13a RPL13a YWHAZ2 RPL13a RPL13a RPL13a 18S RPL13a RPL13a UBC 
 UBC UBC ActB B2M 18S UBC RPL13a 18S YWHAZ2 YWHAZ2 
Least 
stable 
ActB ActB B2M ActB ActB ActB ActB ActB ActB ActB 
 
Table 5: Normfinder rankings (grouped) 
Normfinder results for the entire dataset or healthy/diseased subsets grouped by different 
criteria (as indicated: top row; datasets, second row; criterion), ranked from highest scoring 
(lowest stability value) to lowest scoring. Grouped analysis also suggests the best pair of genes 
for normalization (third row), (not necessarily the highest scoring individually). Bold: stability 









Figure 1:  geNorm analysis 
Representative outputs of the geNorm algorithm. geNorm ranking (left to right: least stable 
to most stable) for the entire dataset (a); or for our healthy muscle panel only (b). Dashed 
line indicates accepted threshold for use as a reference gene (M<0.5). 
 
Figure 2: BestKeeper analysis 
Representative outputs of the BestKeeper algorithm. Coefficient of correlation values for the 
reference gene candidates are shown for the entire dataset (a) or healthy muscle panel (b) 
samples, ranked (left to right) from least stable to most stable. 
 
Figure 3: Normfinder analysis (ungrouped) 
Representative outputs of the Normfinder algorithm. Stability values (left to right: least stable 
to most stable) for the reference gene candidates are shown for the entire dataset (a) or for 
our healthy muscle panel (b). 
 
Figure 4: Dystrophy-associated gene expression 
Expression data for (a) B2M, (b) Myf5 and (c) MEF2C in cDNA prepared from Vastus lateralis 
muscle samples, normalized using the geometric mean of SDHA, RPL13a and HPRT1. Data 
shown as individual samples (●), and means +/- SEM. N=13:9 (healthy:DMD).  **: P<0.005; 
***:P<0.001,****:P<0.0001, (Mann-Whitney U test). 
 
Figure 5: Correlation in relative gene expression of high scoring candidates 
Correlation between HPRT1, SDHA and RPL13a for all muscle samples in our dataset 






























Supplementary Material:  
Supplementary information 1: 
Strengths and weaknesses of reference gene assessment software packages: 
 
geNorm: geNorm analysis employs an iterative pairwise approach, assessing all genes for 
pairwise variation in expression across the dataset, discarding the lowest scoring, then 
repeating the analysis until only a pair of genes remains. The resulting scores are presented 
as a ranked list of expression stability. In essence, this method determines which two genes 
show the most closely shared pattern of variation, and how closely the other candidate genes 
mirror this variation. As such, this method is relatively tolerant of ‘noisy’ datasets: the extent 
of variation between individual samples is less important than the extent to which any given 
genes share this variation. This method is not without caveats, however: pairwise scoring is 
highly sensitive, and omission or inclusion of a single outlying sample can ‘reshuffle’ the 
scoring entirely. Perhaps counter-intuitively, consistently noisy datasets are handled well, 
while relatively stable expression datasets with scant outliers must be handled with caution. 
In addition, the geNorm scoring necessarily assumes that the variation observed is due solely 
to differences in RNA extraction/cDNA synthesis rather than genuine differences in gene 
expression, and thus places the onus on the operator to employ a panel of candidate genes 
sufficiently diverse as to show no significant functional overlap: two genes associated with 
muscle repair would be expected to score highly via geNorm simply because both genes are 
subject to similar transcriptional regulation.  
The geNorm software (as originally released) is no longer freely available, instead having been 
integrated into the commercial qBase software package 
(http://www.biogazelle.com/qbaseplus), however a Microsoft-office compatible copy of the 
original excel macro is available at http://ulozto.net/xsFueHSA/genorm-v3-zip. 
 
Bestkeeper: the Bestkeeper method adopts a different correlation-based approach, instead 
taking the individual Cq values for each sample, for all candidate reference genes, and 
generating the geometric mean: the bestkeeper value. The bestkeeper dataset thus 
represents the consensus change in expression, between samples, for the dataset as a whole. 
By comparing the correlation of individual candidate genes with this bestkeeper, the 
individual genes that best reflect the behaviour of the entire dataset can be determined. As 
with geNorm, this approach assumes the panel of candidate genes do not share 
transcriptional regulation, but as the ‘bestkeeper’ values are derived from multiple genes, the 
method is less sensitive to individual sample outliers. Instead, this method potentially exhibits 
sensitivity to individual poorly-stable genes (rather than individual samples), favouring the 
use of a reasonably large panel of candidate reference genes (at least 5-6, ideally more). 
The bestkeeper spreadsheet can be obtained from http://www.gene-
quantification.de/bestkeeper.html 
 
Normfinder: the Normfinder algorithm ranks candidate genes based on expression stability 
(lowest overall variation in expression), and can do so both for the dataset as a whole (overall 
stability) or as a function of user-specified sample groups, measuring expression stability both 
within groups and between groups for each gene: a gene that shows minimal overall variation 
may nevertheless exhibit distinct group-specific variation. Normfinder thus can identify 
suitable reference genes based on stability of expression alone: while this analysis thus 
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favours less noisy datasets, it eliminates pairwise/correlation-based scoring and is thus 
inherently less sensitive to addition or removal of specific genes, relaxing the requirement for 
truly independently-regulated candidates. As such, it offers a valuable counterpart to the 
strictly correlation-based approaches of geNorm and Bestkeeper. Moreover, the algorithm’s 
facility for group-based analysis is particularly powerful when combined with large datasets 
capable of being grouped by multiple criteria.  
The Normfinder plugin can be obtained from http://moma.dk/normfinder-software 
 









Supplementary figure 1: Animals/muscles used in this study 
Left hand schematic: Animal IDs and ages at biopsy collection. Filled segments indicate muscle 
samples: Dystrophic samples in dark grey, healthy in light grey. Littermates are indicated by 
matching letters. D1 and D2 (lower box: cross-hatched segments) were not enrolled on the 
natural history study, but were euthanized at 14 and 17 months of age respectively.  
Right hand boxes: muscle tissues taken. All natural history samples were from vastus lateralis 






Supplementary figure 2: Cq distribution and coverage 
Mean Cq values for every sample, for every gene (as indicated). Lower Cq values indicate 
higher expression. Dots: sample Cq values; Boxes: 25th/75th percentiles; Whiskers: minimum 
and maximum values. 
 
 
Supplementary figure 3: geNorm analysis (pairwise rankings) 
geNorm results for the entire dataset (top left) or paired subsets; healthy and dystrophic (all), 
or dystrophic/healthy alone, paired with subdivision by all samples, natural history samples 
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or muscle panel samples as indicated, individually ranked left to right from least stable to 




Supplementary figure 4: geNorm analysis (pairwise variation) 
geNorm results for the entire dataset or paired subsets (as indicated) showing change in 
pairwise variation as number of reference genes increase. In all cases increasing number of 
genes to three or four (second/third colums) lowers variation, but the best pair passes the 






Supplementary figure 5: Bestkeeper analysis (coefficient of correlation) 
Bestkeeper results for the entire dataset or paired subsets (as indicated), ranked left to right 






Supplementary figure 6: Normfinder analysis (ungrouped) 
Normfinder results for the entire ungrouped dataset or paired subsets (as indicated), ranked 








Supplementary figure 7: Normfinder analysis (grouped) 
Normfinder results for the entire dataset or subsets grouped by different paired criteria (as 
indicated), ranked left to right from least stable to most stable. The best pair of genes 
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Supplementary table 1: Extended Normfinder analysis (grouped) 
Normfinder results for the natural history samples (further analysed by dystrophic/healthy alone) or for our panel of muscles, grouped by 
different criteria (as indicated: top row; datasets, second row; criterion), ranked from highest scoring (lowest stability value) to lowest scoring. 
Grouped analysis also suggests the best pair of genes for normalization (third row), (not necessarily the highest scoring individually). Bold: 
stability <0.4; italics: stability > 0.8 
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